A monoclonal antibody developed by Genentech (Roche) for multiple sclerosis (MS) has been approved for marketing in the US, the first therapy to show a delay in disability for those with progressive forms of the disease. In clinical trials, Ocrevus performed better than Rebif, the standard of care.
